Evidence map›Paper›PMID 24798291›Full record

ArticleAntimicrobial agents and chemotherapy2014

Structural changes and differentially expressed genes in Pseudomonas aeruginosa exposed to meropenem-ciprofloxacin combination.

Vera Lúcia Dias Siqueira, Rosilene Fressatti Cardoso, Katiany Rizzieri Caleffi-Ferracioli, Regiane Bertin de Lima Scodro, Maria Aparecida Fernandez, Adriana Fiorini, Tania Ueda-Nakamura, Benedito Prado Dias-Filho, Celso Vataru Nakamura

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. The Role of the SOS Response in the Adaptation ofCurrent issues in molecular biology · 2026
    Review
  3. Review
  4. Synergistic potential of LeuBMC microbiology · 2024
    Article
  5. Increased tolerance to commonly used antibiotics in aMicrobiology (Reading, England) · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Research Progress on Bacterial Membrane Vesicles and Antibiotic Resistance.International journal of molecular sciences · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Vera Lúcia Dias SiqueiraPostgraduate Program in Pharmaceutical Sciences, State University of Maringa, Maringá, Paraná, Brazil Department of Clinical Analysis and Biomedicine, State University of Maringa, Maringá, Paraná, Brazil.
Rosilene Fressatti CardosoDepartment of Clinical Analysis and Biomedicine, State University of Maringa, Maringá, Paraná, Brazil.
Katiany Rizzieri Caleffi-FerracioliDepartment of Clinical Analysis and Biomedicine, State University of Maringa, Maringá, Paraná, Brazil.
Regiane Bertin de Lima ScodroDepartment of Clinical Analysis and Biomedicine, State University of Maringa, Maringá, Paraná, Brazil.
Maria Aparecida FernandezDepartment of Cellular Biology and Genetics, State University of Maringa, Maringá, Paraná, Brazil.
Adriana FioriniDepartment of Clinical Analysis and Biomedicine, State University of Maringa, Maringá, Paraná, Brazil.
Tania Ueda-NakamuraPostgraduate Program in Pharmaceutical Sciences, State University of Maringa, Maringá, Paraná, Brazil.
Benedito Prado Dias-FilhoPostgraduate Program in Pharmaceutical Sciences, State University of Maringa, Maringá, Paraná, Brazil.
Celso Vataru NakamuraPostgraduate Program in Pharmaceutical Sciences, State University of Maringa, Maringá, Paraná, Brazil cvnakamura@uem.br.
Universidade Estadual de Maringá · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effect of a meropenem-ciprofloxacin combination (MCC) on the susceptibility of multidrug-resistant (MDR) Pseudomonas aeruginosa (MRPA) clinical isolates was determined using checkerboard and time-kill curve techniques. Structural changes and differential gene expression that resulted from the synergistic action of the MCC against one of the P. aeruginosa isolates (1071-MRPA]) were evaluated using electron microscopy and representational difference analysis (RDA), respectively. The differentially expressed, SOS response-associated, and resistance-associated genes in 1071-MRPA exposed to meropenem, ciprofloxacin, and the MCC were monitored by quantitative PCR. The MCC was synergistic against 25% and 40.6% of MDR P. aeruginosa isolates as shown by the checkerboard and time-kill curves, respectively. The morphological and structural changes that resulted from the synergistic action of the MCC against 1071-MRPA were a summation of the effects observed with each antimicrobial alone. One exception included outer membrane vesicles, which were seen in a greater amount upon ciprofloxacin exposure but were significantly inhibited upon MCC exposure. Cell wall- and DNA repair-associated genes were differentially expressed in 1071-MRPA exposed to meropenem, ciprofloxacin, and the MCC. However, some of the RDA-detected, resistance-associated, and SOS response-associated genes were expressed at significantly lower levels in 1071-MRPA exposed to the MCC. The MCC may be an alternative for the treatment of MDR P. aeruginosa. The effect of this antimicrobial combination may be not only the result of a summation of the effects of meropenem and ciprofloxacin but also a result of differential action that likely inhibits protective mechanisms in the bacteria.

Indexed as

Anti-Bacterial AgentsBrazilCiprofloxacinColony Count, MicrobialDNA, BacterialDrug CombinationsDrug Resistance, Multiple, BacterialGene Expression Regulation, BacterialGenes, BacterialHumansMeropenemMicrobial Sensitivity TestsPolymerase Chain ReactionPseudomonas aeruginosaPseudomonas InfectionsRNA, BacterialAnti-Bacterial AgentsCiprofloxacinDNA, BacterialDrug CombinationsMeropenemRNA, BacterialThienamycins

Identifiers

PMID24798291
PMCPMC4068605
OpenAlexW2131164257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.